To the full analysis
AdaptHealth stock: growth
AHCOAdaptHealth reported $3.24B in revenue for fiscal 2025, down 0.5% on the prior year, up 25.2% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
38.4%
per year from 2016 to 2025, per share 17.6%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
26%
per year from 2016 to 2025, per share 7.1%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2016 | |
|---|---|---|
| Revenue | 25.2% | 38.4% |
| Revenue per share | 3.6% | 17.6% |
| Earnings | no data | no data |
| Earnings per share | no data | no data |
| Free cash flow | 7.1% | 26.0% |
| Free cash flow per share | −11.4% | 7.1% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2016 | $174.32M | −$3.79M | $27.47M |
| 2017 | $192.56M | −$693 | $39.08M |
| 2018 | $345.28M | $2.09M | $58.48M |
| 2019 | $529.64M | −$21.34M | $39.09M |
| 2020 | $1.06B | −$161.63M | $155.88M |
| 2021 | $2.45B | $156.18M | $72.37M |
| 2022 | $2.97B | $69.32M | −$17.56M |
| 2023 | $3.2B | −$678.9M | $143.2M |
| 2024 | $3.26B | $90.42M | $235.78M |
| 2025 | $3.24B | −$70.79M | $219.38M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 7 Aug 2026)
- Valuation signal Overvalued since 8 Nov 2026, previously Fairly valued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.